SCHEMBL972900

SCHEMBL972900

CC(C)(C)OC(=O)N1CCC(Nc2nccs2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.49
USP30 Q70CQ3 6/20 0.49
GPR119 Q8TDV5 2/20 0.49
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ALDH1A1 P00352 2/20 0.46
BTK Q06187 1/20 0.46
NPC1 O15118 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PIK3CD O00329 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
EPHX1 P07099 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13326821 1.00 CNR1 (0.49) CNR1USP30GPR119ADORA3ADORA2A
SCHEMBL3449537 0.93 ALDH1A1 (0.54) USP30GPR119ALDH1A1NPC1MAPT
SCHEMBL973607 0.90 ADORA2A (0.45) CNR1USP30GPR119ADORA3ADORA2A
SCHEMBL13359894 0.83 GAA (0.41) CNR1ADORA3ADORA2AADORA2BNPC1
SCHEMBL28898382 0.81 NPC1 (0.62) GPR119NPC1RAB9A
SCHEMBL26775806 0.81 USP30 (0.46) USP30ALDH1A1BTKNPC1MAPT
SCHEMBL889083 0.80 USP30 (0.50) USP30ALDH1A1BTKNPC1MAPT
SCHEMBL23702764 0.78 IDH1 (0.51) USP30GPR119ALDH1A1BTKNPC1
SCHEMBL23708736 0.78 IDH1 (0.51) USP30GPR119ALDH1A1BTKNPC1
SCHEMBL2618734 0.78 PARP1 (0.46) CNR1USP30GPR119ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871999-B2 Substituted thiazoles and their use for producing drugs GRUENENTHAL GMBH (DE) 2011-01-18 US disclosed
EP-1968957-B1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2010-01-20 EP disclosed
US-20090176756-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-07-09 US disclosed
WO-2007079960-A9 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2008-10-23 WO disclosed
EP-1968957-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP disclosed
WO-2007079960-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176756-A1 SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS TPMT, SLC5A2, DPP4 CNR1 2025/4885USP30 4362/4885GPR119 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.